Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection
ObjectivePatients with COVID-19 presented with an elevated prevalence of antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We analysed the persistence of aPL and their association with the clinical outcomes during hospitalisation in a cohort of COVID-19 patient...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.911979/full |
| _version_ | 1818214243349037056 |
|---|---|
| author | Gerard Espinosa Gerard Espinosa Carles Zamora-Martínez Albert Pérez-Isidro Albert Pérez-Isidro Daniela Neto Luz Yadira Bravo-Gallego Sergio Prieto-González Sergio Prieto-González Odette Viñas Ana Belen Moreno-Castaño Ana Belen Moreno-Castaño Estíbaliz Ruiz-Ortiz Estíbaliz Ruiz-Ortiz Ricard Cervera Ricard Cervera The COVAPS-CLINIC Study Group Investigators Alex Almuedo Giuseppe Barilaro Luz Yadira Bravo-Gallego Daniel Camprubí Júlia Calvo Aina Capdevila-Reniu Irene Carbonell Ricard Cervera Georgina Espígol-Frigolé Gerard Espinosa Cristina Gabara Priscila Giavedoni Ignacio Grafia Andrea Ladino Gema Maria Lledó-Ibáñez Ana Matas-García Pere Millat Pedro Juan Moreno Ana Belen Moreno-Castaño Magdalena Muelas José Muñoz José Naval Joan Padrosa Martina Pellicé María Jesús Pinazo Sergio Prieto-González Roberto Ríos-Garcés Natalia Rodríguez Olga Rodríguez-Núñez Estibaliz Ruiz-Ortiz Ruth Sotil Adrià Tomé Helena Ventosa Odette Viñas Carles Zamora-Martínez |
| author_facet | Gerard Espinosa Gerard Espinosa Carles Zamora-Martínez Albert Pérez-Isidro Albert Pérez-Isidro Daniela Neto Luz Yadira Bravo-Gallego Sergio Prieto-González Sergio Prieto-González Odette Viñas Ana Belen Moreno-Castaño Ana Belen Moreno-Castaño Estíbaliz Ruiz-Ortiz Estíbaliz Ruiz-Ortiz Ricard Cervera Ricard Cervera The COVAPS-CLINIC Study Group Investigators Alex Almuedo Giuseppe Barilaro Luz Yadira Bravo-Gallego Daniel Camprubí Júlia Calvo Aina Capdevila-Reniu Irene Carbonell Ricard Cervera Georgina Espígol-Frigolé Gerard Espinosa Cristina Gabara Priscila Giavedoni Ignacio Grafia Andrea Ladino Gema Maria Lledó-Ibáñez Ana Matas-García Pere Millat Pedro Juan Moreno Ana Belen Moreno-Castaño Magdalena Muelas José Muñoz José Naval Joan Padrosa Martina Pellicé María Jesús Pinazo Sergio Prieto-González Roberto Ríos-Garcés Natalia Rodríguez Olga Rodríguez-Núñez Estibaliz Ruiz-Ortiz Ruth Sotil Adrià Tomé Helena Ventosa Odette Viñas Carles Zamora-Martínez |
| author_sort | Gerard Espinosa |
| collection | DOAJ |
| description | ObjectivePatients with COVID-19 presented with an elevated prevalence of antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We analysed the persistence of aPL and their association with the clinical outcomes during hospitalisation in a cohort of COVID-19 patients.Patients and MethodsWe conducted a prospective study including consecutive hospitalised patients with COVID-19 from Hospital Clínic of Barcelona between March 28th and April 22nd, 2020. Clinical outcomes during hospitalisation were thrombosis, intensive care unit (ICU) admission, and severe ventilatory failure. We determined both criteria and non-criteria aPL. Of note, in those patients with a positive result in the first determination, a second sample separated by at least 12 weeks was drawn to test the persistence of aPL.ResultsOne hundred and fifty-eight patients (59.5% men) with a mean age of 61.4 ± 14.9 years old were included. Thrombosis was present in 28 (17.7%) patients, severe respiratory failure in 47 (30.5%), and 30 (18.9%) patients were admitted to ICU. Sixteen (28.6%) patients were positive for the criteria aPL at both determinations and only two (3.6%) of them suffered from thrombosis during hospitalisations (both had aCL IgG). However, they presented with low titers of aCL. Of note, aPL were not related to thrombosis, ICU admission or severe respiratory failure.ConclusionAlthough aPL were prevalent in our cohort of hospitalised COVID-19 patients and they were persistent in half of tested patients, most determinations were at low titers and they were not related to worse clinical outcomes. |
| first_indexed | 2024-12-12T06:17:05Z |
| format | Article |
| id | doaj.art-53b05196ad4f4b00976405b5241bd202 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T06:17:05Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-53b05196ad4f4b00976405b5241bd2022022-12-22T00:34:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.911979911979Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 InfectionGerard Espinosa0Gerard Espinosa1Carles Zamora-Martínez2Albert Pérez-Isidro3Albert Pérez-Isidro4Daniela Neto5Luz Yadira Bravo-Gallego6Sergio Prieto-González7Sergio Prieto-González8Odette Viñas9Ana Belen Moreno-Castaño10Ana Belen Moreno-Castaño11Estíbaliz Ruiz-Ortiz12Estíbaliz Ruiz-Ortiz13Ricard Cervera14Ricard Cervera15The COVAPS-CLINIC Study Group InvestigatorsAlex AlmuedoGiuseppe BarilaroLuz Yadira Bravo-GallegoDaniel CamprubíJúlia CalvoAina Capdevila-ReniuIrene CarbonellRicard CerveraGeorgina Espígol-FrigoléGerard EspinosaCristina GabaraPriscila GiavedoniIgnacio GrafiaAndrea LadinoGema Maria Lledó-IbáñezAna Matas-GarcíaPere MillatPedro Juan MorenoAna Belen Moreno-CastañoMagdalena MuelasJosé MuñozJosé NavalJoan PadrosaMartina PellicéMaría Jesús PinazoSergio Prieto-GonzálezRoberto Ríos-GarcésNatalia RodríguezOlga Rodríguez-NúñezEstibaliz Ruiz-OrtizRuth SotilAdrià ToméHelena VentosaOdette ViñasCarles Zamora-MartínezDepartment of Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainDepartment of Internal Medicine, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainDepartment of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, SpainDepartment of Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, SpainDepartment of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainDepartment of Internal Medicine, Hospital Clínic de Barcelona, Barcelona, SpainDepartment of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainDepartment of Pathology, Center for Biomedical Diagnosis, Hospital Clinic, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainDepartment of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, SpainDepartment of Autoimmune Diseases, Hospital Clínic de Barcelona, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainObjectivePatients with COVID-19 presented with an elevated prevalence of antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We analysed the persistence of aPL and their association with the clinical outcomes during hospitalisation in a cohort of COVID-19 patients.Patients and MethodsWe conducted a prospective study including consecutive hospitalised patients with COVID-19 from Hospital Clínic of Barcelona between March 28th and April 22nd, 2020. Clinical outcomes during hospitalisation were thrombosis, intensive care unit (ICU) admission, and severe ventilatory failure. We determined both criteria and non-criteria aPL. Of note, in those patients with a positive result in the first determination, a second sample separated by at least 12 weeks was drawn to test the persistence of aPL.ResultsOne hundred and fifty-eight patients (59.5% men) with a mean age of 61.4 ± 14.9 years old were included. Thrombosis was present in 28 (17.7%) patients, severe respiratory failure in 47 (30.5%), and 30 (18.9%) patients were admitted to ICU. Sixteen (28.6%) patients were positive for the criteria aPL at both determinations and only two (3.6%) of them suffered from thrombosis during hospitalisations (both had aCL IgG). However, they presented with low titers of aCL. Of note, aPL were not related to thrombosis, ICU admission or severe respiratory failure.ConclusionAlthough aPL were prevalent in our cohort of hospitalised COVID-19 patients and they were persistent in half of tested patients, most determinations were at low titers and they were not related to worse clinical outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2022.911979/fullCOVID - 19antiphospholipid antibodiesantiphospholipid syndrome - immunologydiagnosisthrombosis - immunologypersistence |
| spellingShingle | Gerard Espinosa Gerard Espinosa Carles Zamora-Martínez Albert Pérez-Isidro Albert Pérez-Isidro Daniela Neto Luz Yadira Bravo-Gallego Sergio Prieto-González Sergio Prieto-González Odette Viñas Ana Belen Moreno-Castaño Ana Belen Moreno-Castaño Estíbaliz Ruiz-Ortiz Estíbaliz Ruiz-Ortiz Ricard Cervera Ricard Cervera The COVAPS-CLINIC Study Group Investigators Alex Almuedo Giuseppe Barilaro Luz Yadira Bravo-Gallego Daniel Camprubí Júlia Calvo Aina Capdevila-Reniu Irene Carbonell Ricard Cervera Georgina Espígol-Frigolé Gerard Espinosa Cristina Gabara Priscila Giavedoni Ignacio Grafia Andrea Ladino Gema Maria Lledó-Ibáñez Ana Matas-García Pere Millat Pedro Juan Moreno Ana Belen Moreno-Castaño Magdalena Muelas José Muñoz José Naval Joan Padrosa Martina Pellicé María Jesús Pinazo Sergio Prieto-González Roberto Ríos-Garcés Natalia Rodríguez Olga Rodríguez-Núñez Estibaliz Ruiz-Ortiz Ruth Sotil Adrià Tomé Helena Ventosa Odette Viñas Carles Zamora-Martínez Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection Frontiers in Immunology COVID - 19 antiphospholipid antibodies antiphospholipid syndrome - immunology diagnosis thrombosis - immunology persistence |
| title | Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection |
| title_full | Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection |
| title_fullStr | Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection |
| title_full_unstemmed | Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection |
| title_short | Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection |
| title_sort | persistent antiphospholipid antibodies are not associated with worse clinical outcomes in a prospective cohort of hospitalised patients with sars cov 2 infection |
| topic | COVID - 19 antiphospholipid antibodies antiphospholipid syndrome - immunology diagnosis thrombosis - immunology persistence |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.911979/full |
| work_keys_str_mv | AT gerardespinosa persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT gerardespinosa persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT carleszamoramartinez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT albertperezisidro persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT albertperezisidro persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT danielaneto persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT luzyadirabravogallego persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT sergioprietogonzalez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT sergioprietogonzalez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT odettevinas persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT anabelenmorenocastano persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT anabelenmorenocastano persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT estibalizruizortiz persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT estibalizruizortiz persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ricardcervera persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ricardcervera persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT thecovapsclinicstudygroupinvestigators persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT alexalmuedo persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT giuseppebarilaro persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT luzyadirabravogallego persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT danielcamprubi persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT juliacalvo persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ainacapdevilareniu persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT irenecarbonell persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ricardcervera persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT georginaespigolfrigole persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT gerardespinosa persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT cristinagabara persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT priscilagiavedoni persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ignaciografia persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT andrealadino persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT gemamarialledoibanez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT anamatasgarcia persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT peremillat persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT pedrojuanmoreno persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT anabelenmorenocastano persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT magdalenamuelas persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT josemunoz persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT josenaval persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT joanpadrosa persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT martinapellice persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT mariajesuspinazo persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT sergioprietogonzalez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT robertoriosgarces persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT nataliarodriguez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT olgarodrigueznunez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT estibalizruizortiz persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT ruthsotil persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT adriatome persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT helenaventosa persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT odettevinas persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection AT carleszamoramartinez persistentantiphospholipidantibodiesarenotassociatedwithworseclinicaloutcomesinaprospectivecohortofhospitalisedpatientswithsarscov2infection |